CXCL8 and rheumatoid arthritis: Dasatinib, a Src kinase inhibitor, is shown to inhibit the production of TNF-α, IL-6, and IL-8 from macrophages, monocytes and RA-synovial fibroblasts as well as dasatinib affects the activations of these cells [26].